Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Research comparing hormone therapy (HT) doses, regimens, and routes of delivery in relation to cardiovascular disease (CVD) outcomes has been limited. This study directly compared different estrogen doses, routes of delivery, and HT formulations in postmenopausal women in relation to the risk of coronary heart disease (CHD), stroke, CVD mortality, total CVD, and all-cause mortality. METHODS: The Women's Health Initiative Observational Study is a multicenter prospective cohort study that was conducted at 40 US sites. Analyses included 93,676 postmenopausal women aged 50 to 79 years at study entry who were recruited from September 1994 to December 1998, with annual follow-up through August 14, 2009. RESULTS: The mean follow-up was 10.4 years. In direct comparisons, oral estradiol was associated with lower hazard ratios (HRs) for stroke than oral conjugated equine estrogens (CEE; HR, 0.64; 95% CI, 0.40-1.02), but statistical power was limited. Similarly, transdermal estradiol was associated with a moderate but nonsignificantly lower risk of CHD compared with oral CEE (HR, 0.63; 95% CI, 0.37-1.06). For other outcomes, comparisons revealed no appreciable differences by estrogen doses, formulations, or routes of delivery. Absolute risks of CVD events and all-cause mortality were markedly lower in younger women compared with older women. CONCLUSIONS: In direct comparisons, various HT doses and regimens are associated with similar rates of cardiovascular events and all-cause mortality. However, oral estradiol may be associated with a lower risk of stroke, and transdermal estradiol may be associated with a lower risk of CHD, compared with conventional-dose oral CEE. Additional research is needed to confirm these hypotheses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 3×
“Previous randomized studies have reported an increased CVD risk with HT use that is divergent from observational results.(1,5,11,21) With regard to stroke, randomized trials and observational studies have been concordant, showing an overall increased risk with HT.”
BackgroundMethodSelf-citationPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 1×
“recent analyses from the WHI-CT showing that women who initiate HT closer to the menopausal transition tend to have more favorable CHD outcomes with HT than those initiating HT late in menopause.(18) Although we found similar HRs in younger and older women, our statistical power to address these issues was limited.”
MethodSelf-citationComparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316 · cited 1×
“ences in pharmacodynamic estrogen receptor affinity, metabolism, or other variablesVhas been suggested but has not been well explored.(12,13)”
Background
Cited by
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Self-citationTreatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“Although observational studies suggest that a dermal route of ET may carry a lower risk of MI (101, 102), a meta-analysis reported no significant difference in CHD outcomes between oral and transdermal MHT (4).”
BackgroundEndogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women
Zhao, D., Guallar, E., Ouyang, P., Subramanya, V., Vaidya, D., Ndumele, C. E., Lima, J. A., Allison, M. A., Shah, S. J., Bertoni, A. G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.083 · Cited by 432
Kaliannan, K., Robertson, R. C., Murphy, K., Stanton, C., Kang, C., Wang, B., Hao, L., Bhan, A. K., & Kang, J. X. (2018) · Microbiome · doi:10.1186/s40168-018-0587-0 · Cited by 253
A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms
Park, J. Y., & Kim, K. H. (2016) · Climacteric · doi:10.1080/13697137.2016.1238453 · Cited by 32
Metadata
- Authors
- Shufelt, C. L., Merz, C. N. B., Prentice, R. L., Pettinger, M. B., Rossouw, J. E., Aroda, V. R., Kaunitz, A. M., Lakshminarayan, K., Martin, L. W., Phillips, L. S., & Manson, J. E.
- Venue
- Menopause
- Published
- 2014-03
- Volume
- 21
- Issue
- 3
- Pages
- 260-266
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2083031515
- Cited by
- 106
- References
- 4
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. https://app.cochat.ai/papers/10.1097/gme.0b013e31829a64f9
- The paper
- Shufelt, C. L., Merz, C. N. B., Prentice, R. L., Pettinger, M. B., Rossouw, J. E., Aroda, V. R., Kaunitz, A. M., Lakshminarayan, K., Martin, L. W., Phillips, L. S., & Manson, J. E. (2014). Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. Menopause. https://doi.org/10.1097/gme.0b013e31829a64f9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.